Meeting
2021 ASCO Annual Meeting
Safety and unique pharmacokinetic profile of ARX788, a site-specific ADC, in heavily pretreated patients with HER2-overexpresing solid tumors: Results from two phase 1 clinical trials.
Authors
Sara A. Hurvitz
David Geffen School of Medicine, University of California, Los Angeles/ Jonsson Comprehensive Cancer Center, Los Angeles, CA
Sara A. Hurvitz , Haeseong Park , Sophia Frentzas , Catherine M. Shannon , Katharine Cuff , Richard Wilhelm Eek , George Thomas Budd , Amelia McCartney , Joyce O'Shaughnessy , Janice M. Lu , Jian Zhang , Dongmei Ji , Weina Shen , Matt Li , Jinchun Yan , Gang Xia , Yanping Ji , Sulan Yao , Gaozhun Xiong , Xichun Hu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Clinical Trial Registration Number
NCT032550070
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 1038)
DOI
10.1200/JCO.2021.39.15_suppl.1038
Abstract #
1038
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase I study of nelmastobart (hSTC810), an anti-BTN1A1 antibody, in patients with advanced solid tumors.
First Author: Soohyeon Lee
Poster
2023 ASCO Annual Meeting
Phase 1 study of indenoisoquinoline LMP744 in adults with relapsed solid tumors and lymphomas.
First Author: Brian Ko
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Safety and preliminary efficacy of MIL93 in patients with advanced solid tumors: The monotherapy part of a phase 1 trial.
First Author: Jing Huang
Poster
2022 ASCO Annual Meeting
Safety, pharmacokinetics (PK), and clinical efficacy of ICP-723, a highly selective next-generation pan-TRK inhibitor, in patients with solid tumor.
First Author: Xiao-Li Wei